Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2003
11/06/2003CA2483102A1 Treatment and prevention of pulmonary conditions
11/06/2003CA2483093A1 Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
11/06/2003CA2483007A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003CA2483005A1 Treatment of metabolic syndrome
11/06/2003CA2482996A1 Vitamin d3 upregulated protein 1 treats post-infarct myocardial ischemia
11/06/2003CA2482711A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003CA2480845A1 Adipocyte complement related protein zacrp8
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003CA2479992A1 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
11/05/2003EP1358910A1 Methods and means for prevention, inhibition and therapy of cancer
11/05/2003EP1358889A1 Medicinal compositions for treating lower uropathy
11/05/2003EP1358887A1 Composition of traditional chinese medicines for preventing and treating cerebrovascular disease
11/05/2003EP1358883A1 Re-epithelializing pharmaceutical compositions containing xanthan gum
11/05/2003EP1358881A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
11/05/2003EP1358879A1 Antilipemic agents
11/05/2003EP1358869A1 Biologically active compounds for the modificaton of bodily odours
11/05/2003EP1358868A2 Cosmetic composition for increasing hair growth and/or for preventing or delaying hair loss
11/05/2003EP1358485A2 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
11/05/2003EP1358354A1 Method for identifying compounds modulating reverse cholesterol transport
11/05/2003EP1358348A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/05/2003EP1358336A2 Human serine-threonine kinase
11/05/2003EP1358334A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
11/05/2003EP1358330A2 Transporters and ion channels
11/05/2003EP1358329A2 Lipid-associated molecules
11/05/2003EP1358328A2 Regulation of human serotonin-like g protein-coupled recepter
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358325A2 Protein modification and maintenance molecules
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358188A2 Antagonists of mcp-1 function and methods of use thereof
11/05/2003EP1358178A2 Sulfonamide lactam inhibitors of factor xa
11/05/2003EP1358177A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
11/05/2003EP1358163A1 Melanocortin receptor agonists
11/05/2003EP1358153A1 Ophthalmic compositions for treating ocular hypertension
11/05/2003EP1358150A1 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
11/05/2003EP1357978A2 Hematopoietic stem cell gene therapy
11/05/2003EP1357977A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
11/05/2003EP1357974A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
11/05/2003EP1357944A2 Perylenequinones for use with immunotherapy agents
11/05/2003EP1357941A2 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
11/05/2003EP1357935A2 Method of reducing side effects of chemotherapy in cancer patients
11/05/2003EP1357930A2 Histidine-rich glycoprotein
11/05/2003EP1357921A2 Bacterial isolates from organisms that respire at least partially through their skin and biologically active extracts derived therefrom
11/05/2003EP1357915A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/05/2003EP1357908A2 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
11/05/2003EP1357905A2 A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
11/05/2003EP1357897A2 Delivery of biologically active agents
11/05/2003EP1357881A2 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
11/05/2003EP1357855A2 Ophthalmic compositions for treating ocular hypertension
11/05/2003EP1357811A1 Composition and method for smoke detoxification
11/05/2003EP1189749B1 Composite laminate and method for its production
11/05/2003EP1135136B1 Pharmaceutical compositions containing olanzapine-n-oxide
11/05/2003EP1023069B1 Nicotine compositions and methods of formulation thereof
11/05/2003EP1007034B1 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents
11/05/2003EP0981362B1 Use of glp-2 agonists enhancing functioning of the upper gastrointestinal tract
11/05/2003EP0960197A4 GENES FROM 20q13 AMPLICON AND THEIR USES
11/05/2003EP0871432B1 Use of a composition containing polyether block copolymers
11/05/2003EP0839039B1 Paroxetine controlled release compositions
11/05/2003CN1454256A The high bone mass gene of 11q13.3
11/05/2003CN1454254A Purging of cells using viruses
11/05/2003CN1454216A Antibodies to CCR5
11/05/2003CN1454215A Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
11/05/2003CN1454213A Variants of allergenic proteins of the Group2 of dermatophagoides
11/05/2003CN1454205A Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
11/05/2003CN1454091A Immunostimulatory nucleic acids
11/05/2003CN1454090A Compositions and methods for improving cardiovascular function
11/05/2003CN1454088A Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT)
11/05/2003CN1454084A Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion
11/05/2003CN1454083A Selective androgen receptor modulators and methods for their identification design and use
11/05/2003CN1126566C Luteinizing hormone releasing hormone antagonist and use for medicine preparation for treating prostate hypertrophy and prostate cancer
11/04/2003US6642478 Method for forming a via hole, flexible wiring board using the method, and method for producing the flexible wiring board
11/04/2003US6642411 Compounds and compositions for delivering active agents
11/04/2003US6642363 Bonded to a peptide which promotes cell adhesion and growth; use in drug delivery, cell transplantation and tissue engineering
11/04/2003US6642362 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease
11/04/2003US6642277 And anthocyanin, cardiovascular disorders, inhibits oxidation of plasma LDL, stimulates TGF production and fibrinolysis and is an anticoagulant
11/04/2003US6642271 Potentiating compounds
11/04/2003US6642268 Treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.
11/04/2003US6642266 EP4 receptor selective agonists in the treatment of osteoporosis
11/04/2003US6642252 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer.
11/04/2003US6642237 Inhibitors of HIV protease and inhibitors of HIV replication, used in the prevention or treatment of infection by HIV and treatment for AIDS
11/04/2003US6642235 Administering a therapeutically effective amount of a formulation comprising compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of 5000; for selectively inhibiting reuptake of norepinephrine
11/04/2003US6642219 Treating intermenstrual bleeding in female induced by administration of progestogen-only contraceptive regimen on continuous daily basis, by co-administering, for at least 28 consecutive days, anti-progestogen at specified daily dose
11/04/2003US6642216 Osteoporosis, periodontal diseases
11/04/2003US6642212 Health supplement comprising naturally occurring phytoestrogen selected from any two or more of genistein, daidzein and/or their glycosides
11/04/2003US6642209 Administering effective amount of adenosine receptor agonist to human patient to relieve pain selected from post surgical pain and chronic pain
11/04/2003US6642208 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
11/04/2003US6642010 Identifying, monitoring, and treating women for breast precancer or cancer
11/04/2003US6642008 Assays and therapies for latent viral infection
11/04/2003US6641847 Cranberry seed oil extract and compositions containing components thereof
11/04/2003US6641834 Quinoxaline component is selected from qinoxaline, a (2-imiozoline -2-ylamino) quinoxaline, a 5-bromo-6-(2-imidozolin-2- ylamino) quinoxaline, a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline or derivatives
11/04/2003US6641833 Extended release of paclitaxel by intraperitoneal administration
11/04/2003US6641824 Skin treatment using a new retinoid
11/04/2003US6641810 Methods of using geldanamycin and FK506 to treat peripheral nerve damage
11/04/2003US6641806 Inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, nonbovine proteoglycan such as
11/04/2003US6641611 A coating for an intravascular implant that prevents hyperproliferative vascular disease, includes repamyicin as first agent which acts on calcium independent cellular pathway and second agent is cyclosporin A
11/04/2003US6641571 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
11/04/2003CA2188283C Substituted 1,3-oxathiolanes with antiviral properties
10/2003
10/31/2003CA2444598A1 Compositions useful as inhibitors of gsk-3
10/30/2003WO2003089934A2 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1
10/30/2003WO2003089933A1 Uses of the carbamoyl phosphate synthesis 1 (cps 1) and the fragments thereof for the diagnosis of inflammatory diseases and sepsis
10/30/2003WO2003089903A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1)
1 ... 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 ... 1151